{
  "semaglutide_general": {
    "strategic_synthesis": {
      "title": "Internal Knowledge Base – Strategic Synthesis",
      "insights": [
        {
          "label": "Regulatory Signal",
          "value": "No approved GLP-1 therapies currently indicated for addiction or compulsive behavioral disorders"
        },
        {
          "label": "Internal Hypothesis",
          "value": "Central GLP-1 signaling may modulate reward-driven behaviors independent of metabolic endpoints"
        }
      ],
      "description": "Internal literature scans, post-marketing observations, and mechanistic models consistently point toward non-metabolic applications as the next frontier for GLP-1 lifecycle expansion."
    },
    "cross_indication_comparison": {
      "title": "Cross-Indication Strategic Comparison",
      "dimensions": [
        {
          "dimension": "Commercial Readiness",
          "diabetes_obesity": "Very High",
          "diabetes_obesity_level": "green",
          "emerging_cns": "Medium",
          "emerging_cns_level": "yellow"
        },
        {
          "dimension": "IP Flexibility",
          "diabetes_obesity": "Low",
          "diabetes_obesity_level": "red",
          "emerging_cns": "Moderate",
          "emerging_cns_level": "yellow"
        },
        {
          "dimension": "Strategic White Space",
          "diabetes_obesity": "Low",
          "diabetes_obesity_level": "red",
          "emerging_cns": "High",
          "emerging_cns_level": "green"
        }
      ],
      "description": "Internal prioritization favors emerging behavioral indications where competitive intensity is low and differentiation is structurally defensible."
    }
  },
  "semaglutide_aud": {
    "aud_focus": {
      "title": "Internal Knowledge Base – AUD Focus",
      "insights": [
        {
          "label": "Internal Conviction Level",
          "value": "Moderate–High (pending controlled clinical validation)"
        },
        {
          "label": "Why AUD Survives Kill-Criteria",
          "value": "Clear mechanistic rationale, minimal competitive crowding, and strong unmet clinical need"
        }
      ],
      "description": "Internal screening frameworks consistently rank Alcohol Use Disorder above other exploratory CNS indications due to favorable signal-to-risk asymmetry."
    },
    "risk_flags": {
      "title": "Internal Risk Flags (AUD)",
      "flags": [
        "Translational gap between metabolic and addiction endpoints",
        "Behavioral trial variability and placebo response risk",
        "Payer skepticism without relapse-prevention endpoints"
      ],
      "description": "Despite these risks, AUD remains internally categorized as a 'strategic exploration priority' rather than a speculative edge case."
    }
  }
}
